NCT04952753 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04952753
Title	Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)
Acronym	daNIS-3
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	colorectal adenocarcinoma
Therapies	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BEL \| AUS

Additional content available in CKB BOOST